FTDI
VNDA icon

First Trust Direct Indexing’s Vanda Pharmaceuticals VNDA Stock Holding History

First Trust Direct Indexing’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-657
Closed -$9K – 978
2020
Q4 		$9K Buy
+657
New +$7.91K ﹤0.01% 940

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

First Trust Direct Indexing's VNDA Position: Q1 2021 in Review

First Trust Direct Indexing sold out of Vanda Pharmaceuticals (VNDA) in Q1 2021, closing a stake of 657 shares — an estimated $9K sold.

First Trust Direct Indexing first reported a position in VNDA in Q4 2020 and held it in 1 quarter. The position peaked at $9K in Q4 2020. 189 funds tracked by Wall St. Rank hold VNDA as of Q1 2021.

  • First Trust Direct Indexing reported no remaining Vanda Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • First Trust Direct Indexing sold 657 Vanda Pharmaceuticals shares in Q1 2021, an estimated $9K.
  • First Trust Direct Indexing first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • First Trust Direct Indexing's Vanda Pharmaceuticals position peaked at $9K in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2021.

Based on First Trust Direct Indexing's 13F filing for Q1 2021, filed 14 Apr 2021.